Intra-operative Hyperspectral Imaging in Neurosurgery
NeuroHSI
A Prospective Observational Study to Evaluate the Use of an Intraoperative Hyperspectral Imaging System in Neurosurgery
1 other identifier
observational
81
1 country
1
Brief Summary
Brain surgery operations include brain tumour removal and blood vessel procedures. Each year in the UK, approximately 70,500 patients are diagnosed with a brain tumour, 5,000 of whom undergo surgery. Approximately 1,000 patients undergo blood vessel brain surgery. Brain tumour surgery involves removing as much of the tumour as safely as possible. If all tumour is removed, patients have significantly better outcomes and live longer. However, even with the best hands and the most modern technology currently available, it is often not possible to reliably identify tumour during surgery. Moreover, nerves and blood vessels cannot be reliably identified either during surgery. Yet, they need to be preserved to avoid brain damage. Due to this uncertainty and the need to balance risks, tumour is often left behind. Today, close to 30% of brain tumour patients require repeat surgery owing to tumour left behind during their first surgery. Further surgeries are more difficult, pose additional patient risks and lead to increased healthcare costs with often poor patient outcomes. Newly developed camera systems have the potential to enhance the surgeon's vision to reliably identify tumour and healthy brain structures. Hyperspectral imaging (HSI) is one of the most promising of such technologies. Its core ability is to provide very detailed and rich information that is invisible to the human eye. HSI has demonstrated the potential to provide crucial, but currently unavailable, information about tumour and critical brain structures during surgery. However, HSI data is very complex and requires advanced computer-processing for its interpretation. In this project, we will use a HSI imaging system to record data in 81 patient undergoing brain including 63 patients with brain tumours and 18 patients suffering from brain vessel abnormalities. Using this data we will develop key computer-processing features to enable real-time image interpretation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 11, 2022
CompletedFirst Posted
Study publicly available on registry
March 24, 2022
CompletedStudy Start
First participant enrolled
May 17, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2024
CompletedDecember 1, 2023
November 1, 2023
2.2 years
March 11, 2022
November 30, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Correlation of HSI data with histological analysis of the corresponding biopsied pathological tissue
To correlate HSI data with histological analysis of the corresponding biopsied pathological tissue and to correlate tissue perfusion and tissue oxygenation maps generated from the HSI data with the surgical timeline in patients undergoing neurovascular surgery.
4-6 months
Secondary Outcomes (4)
Tissue perfusion and tissue oxygenation
36 months
Safety of iHSI in Neurosurgery
36 months
AI algorithm specificity
36 months
Qualitative assessment
36 months
Eligibility Criteria
Patients undergoing neuro-oncology and neurovascular surgery
You may qualify if:
- Adult patients aged 18 years and over
- Patients with a diagnosis of a brain tumour (any type), AVM or aneurysm who are scheduled for elective surgery
- Patients able to provide written informed consent
You may not qualify if:
- Patients under 18 years of age
- Patients who have previously had brain surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King's College NHS Foundation Trust
London, SE5 9RS, United Kingdom
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan Shapey
King's College London
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 11, 2022
First Posted
March 24, 2022
Study Start
May 17, 2022
Primary Completion
August 1, 2024
Study Completion
August 1, 2024
Last Updated
December 1, 2023
Record last verified: 2023-11